Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2016-04-19 Earnings Release
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
OLYSIO® sales during the first quarter 2016
Earnings Release Classification · 98% confidence The document is a short announcement titled 'OLYSIO® sales during the first quarter 2016' from Medivir AB. It explicitly states key financial figures (net sales of OLYSIO® for Q1 2016) and royalty amounts for the first quarter. This structure—announcing key period results briefly—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general publication announcement (RPA). It focuses purely on the initial release of period financial highlights. Q1 2016
2016-04-19 English
Försäljning för OLYSIO® under första kvartalet 2016
Earnings Release Classification · 98% confidence The document is a short announcement (2130 chars) from Medivir AB regarding the global net sales of OLYSIO® for the first quarter of 2016 (Q1-2016). It presents key sales figures and royalty amounts. Crucially, the text states: "Medivirs delårsrapport för januari – mars 2016 kommer att publiceras den 28 april 2016..." (Medivir's interim report for January - March 2016 will be published on April 28, 2016...). This indicates the document itself is not the full Interim Report (IR), but rather an early release of key figures preceding the full report publication. Since it provides specific, period-ending financial highlights (Q1 sales), it fits the definition of an Earnings Release (ER). It is not a Report Publication Announcement (RPA) because it contains substantive financial data, not just a notice that a report is coming. Q1 2016
2016-04-19 Swedish
Nya data för simeprevir kommer att presenteras vid EASL:s International Liver Congress 2016
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that new clinical data for their drug simeprevir will be presented at the EASL International Liver Congress 2016. It details the specific abstracts (Late-Breaking Poster and Poster Presentations) that will be presented. This type of announcement, which details upcoming scientific presentations or publications without being the full report itself, fits best under the category of general regulatory announcements or investor relations material. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific legal/governance filing, and it is an announcement about external scientific data presentation, it is classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Given the structure as a press release announcing external conference participation and data presentation abstracts, RNS (Regulatory News Service/General Regulatory Announcement) is the most appropriate fallback for non-standard, time-sensitive corporate updates that aren't explicitly defined elsewhere. The length (under 5,000 characters) also suggests it's an announcement rather than the full data package.
2016-04-11 Swedish
New data for simeprevir will be presented at EASL's International Liver Congress 2016
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that new clinical data for their drug simeprevir will be presented at an upcoming medical conference (EASL's International Liver Congress 2016). It details the abstracts and presentations from the previous year's conference (2015) as context. This type of announcement, which informs the market about scientific data presentation schedules, does not fit neatly into the primary financial filing categories (10-K, ER, IR, etc.). It is a general corporate update regarding scientific progress and future disclosures. Since it is a specific announcement that doesn't match the other specialized codes (like DIV, CAP, MANG, DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements not covered elsewhere.
2016-04-11 English
Årsredovisning 2015
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2015' (Annual Report 2015) for the company Medivir. It contains comprehensive financial data, including income statements, balance sheets, cash flow analyses, management's discussion and analysis (Vd har ordet), and auditor's reports. It is a full-length annual report, not an announcement or a summary, and therefore fits the definition of a 10-K (Annual Report). FY 2015
2016-04-06 Swedish
Annual Report 2015
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2015' and contains comprehensive sections including 'The year in figures', 'CEO's statement', 'Operations', 'Corporate Governance', and 'Financial reports' (Income statements, Balance sheets, etc.). It is a full-year report detailing company activity and financial performance, fitting the definition of an Annual Report (10-K). FY 2015
2016-04-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.